Related Experiment Video
Updated: Dec 14, 2025
08:07
A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
Published on: July 25, 2022
2.9K
Development of a Multi-Antigenic SARS-CoV-2 Vaccine Using a Synthetic Poxvirus Platform.
Flavia Chiuppesi1, Marcela d'Alincourt Salazar2, Heidi Contreras2
1City Of Hope National Medical Center.
Research Square
|July 24, 2020
Summary
A new vaccine platform uses synthetic DNA to create Modified Vaccinia Ankara (MVA) vectors. These vectors rapidly produced a SARS-CoV-2 vaccine candidate, eliciting strong immune responses in mice.
Area of Science:
- Virology
- Immunology
- Vaccine Development
Background:
- Modified Vaccinia Ankara (MVA) is a well-established viral vector for vaccine development.
- Rapid vaccine generation is crucial for emerging infectious diseases like SARS-CoV-2.
Approach:
- Developed a novel three-plasmid system for efficient generation of recombinant MVA vectors from chemically synthesized DNA.
- Created synthetic MVA (sMVA) vectors co-expressing SARS-CoV-2 spike and nucleocapsid antigens.
Key Points:
- sMVA vectors were rapidly produced using the synthetic DNA platform.
- Mice immunized with sMVA vectors showed robust SARS-CoV-2 specific humoral and cellular immune responses.
- Potent neutralizing antibodies were detected in immunized mice.
Conclusions:
- The synthetic DNA platform enables efficient generation of recombinant MVA vectors.
- This approach allows for rapid development of multi-antigenic poxvirus-based vaccine candidates.
- The developed sMVA vectors represent a promising SARS-CoV-2 vaccine candidate.
